12 results about "Notch signalling pathway" patented technology

The invention belongs to the field of biological medicines, and relates to a pharmaceutical composition and application thereof in preparation of medicines for preventing and treating hepatitis B virus. Comprising a nucleic acid drug and a carrier for loading the nucleic acid drug, the carrier can specifically target liver Kupffer cells, the nucleic acid drug is mRNA, and a gene sequence for coding the mRNA comprises nucleotide sequences shown as SEQ ID NO: 1 and SEQ ID NO: 2. The pharmaceutical composition provided by the invention can specifically activate Notch signal channels of Kupffer cells, and can play a role in treating and preventing hepatitis B; meanwhile, the anti-HBV effect of the pharmaceutical composition depends on the participation of Kupffer cells, and the pharmaceutical composition becomes a potential novel strategy for clinical treatment of chronic hepatitis B.

The invention discloses a novel application of a recombinant protein preparation ANXA2 as a NOTCH agonist. The ANXA2 can be used as an agonist of NOTCH2 and NOTCH4, plays a treatment role in NOTCH signal channel related diseases, provides a research tool for the NOTCH signal channel related diseases, and has a wide application prospect.

The present application relates to the field of biological medicine, in particular to a mutant protein related to Notch signal pathway and use thereof. The mutant protein provided by the present application is a mutant Notch1 protein, a mutant DLL4 protein or a mutant JAG1 protein. The mutant protein related to Notch signal pathway provided by the present application: the mutant Notch1 protein has strong activation signal after binding with its ligands DLL4 and JAG1, and is used for regulating the disorder of Notch signal pathway, and can provide a basis for the occurrence mechanism research and development of treatment strategies of developmental disorders, cancers and other diseases.

The present application relates to the technical field of biological diagnosis, and particularly relates to a mutant gene set for tumor molecular typing and application thereof, wherein the mutant gene set comprises 82 mutant genes including DNA methylation modification related genes, histone modification related genes, chromatin remodeling related genes, TCR signal pathway related genes, PI3K-AKT signal pathway related genes, JAK-STAT signal pathway related genes, immune escape related genes, P53 signal pathway related genes, tumor suppressor genes and NOTCH signal pathway related genes. The mutant gene set can be used for molecular typing, targeted therapy and overall survival prediction of intranodal peripheral T-cell lymphoma. The mutant gene set is verified by clinical trials, and is suitable for all primary and relapsed PTCL patients, relapsed or refractory peripheral T-cell lymphoma umbrella study based on genomics typing and PTCL patients receiving different treatment schemes, and has a very wide application range.

The invention discloses a computer-aided drug screening method based on ANXA2 and NOTCH2 / NOTCH4, and relates to a drug screening method based on ANXA2 and NOTCH2 / NOTCH4. The invention provides a brand-new method, system or equipment for screening drugs based on ANXA2 and NOTCH2 / NOTCH4, provides a tool for new drug development and clinical application for NOTCH signal channel related diseases, and has a wide application prospect.

To provide a multispecific antigen-binding molecule which enables Notch signaling pathway activation in a cell of interest in a cell anchorage-dependent manner, a method for producing the multispecific antigen-binding molecule, and a pharmaceutical composition comprising such a multispecific antigen-binding molecule as an active ingredient for activating the Notch signaling pathway in a cell of interest.SOLUTION: The present invention provides multispecific antigen-binding molecules comprising a first antigen-binding moiety that specifically binds to a Notch receptor on a first target cell and a second antigen-binding moiety that specifically binds to an anchor antigen on a second target cell.SELECTED DRAWING: None

The application discloses application of MC1R, in particular, application of an agent for inhibiting MC1R in preparation of a drug for treating colorectal cancer, and belongs to the field of biological medicines. In vitro experiments show that overexpression of MC1R in a colorectal cancer cell line promotes cell proliferation and migration, and inhibits ferroptosis by down-regulating ACSL4 expression, while knockdown of MC1R has an opposite effect. In vivo experiments also find that xenograft tumor volume and weight formed by colorectal cancer cells with knockdown of MC1R are reduced, it is found that MC1R activates a Notch signal pathway, causes ACSL4 expression to be inhibited, thereby inhibiting ferroptosis and further blocking cell growth and migration; high expression of MC1R in colorectal cancer is related to poor prognosis, and is negatively correlated with the ferroptosis level. Targeting MC1R can provide a new strategy for enhancing ferroptosis of colorectal cancer, and provides an important clue for development of targeted therapy for colorectal cancer.

Disclosed herein use of an inhibitor of ATR / CHK1 pathway in treating a NOTCH pathway-related disease, particularly, a disease caused by an aberrant NOTCH signaling pathway, especially a cancer associated with mutation and / or activation of NOTCH. Also disclosed herein a method for treating a NOTCH pathway-related disease, particularly, a disease caused by an aberrant NOTCH signaling pathway, especially a cancer associated with mutation and / or activation of NOTCH with an inhibitor of ATR / CHK1 pathway.

The application belongs to the field of biological medicine, and relates to a kind of pharmaceutical composition and its application in preparation of the drug for preventing and treating hepatitis B virus. Including nucleic acid drug and the carrier loaded with the nucleic acid drug, the carrier can specifically target liver kupffer cell, and the nucleic acid drug is mRNA, and the gene sequence coding the mRNA includes the nucleotide sequence shown in SEQ ID NO:1 and SEQ ID NO:2. The pharmaceutical composition provided by the application can specifically activate the Notch signal pathway of kupffer cell, and can play the effect of treating and preventing hepatitis B. Meanwhile, the anti-HBV effect of the pharmaceutical composition depends on the participation of kupffer cell, and becomes a new type of strategy for potential clinical treatment of chronic hepatitis B.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a small-molecule inhibitor in preparation of a medicine for treating glioblastoma. The small molecule inhibitor is WAY-324631, and the CAS number of the small molecule inhibitor is 438618-43-0. The research discovers that WAY-324631 can stop interaction between KAT7 and CTCF, reduce acetylation of CTCF and inhibit activation of NOTCH signal channels by targeting a binding site between KAT7 and CTCF, so that the malignant progression of glioblastoma is slowed down. In addition, the small-molecule inhibitor is combined with TMZ for use, so that the sensitivity of GBM cells to TMZ can be remarkably improved. The invention provides a new target and strategy for treatment of GBM.

The invention discloses serine and L-lysine salts as shown in a formula I or a formula II as well as a preparation method and application of the serine and L-lysine salts in nervous system disease autism spectrum disorders, the synthesized serine and L-lysine salts are lower in heavy metal content and higher in stability compared with serine or lysine, and the application of the serine and L-lysine salts in nervous system disease autism spectrum disorders is promoted. According to the present invention, the problems of high heavy metal content and unstable storage when the two amino acids are separately used are overcome, the serine and the L-lysine form the salt, and the NICD and Hes1 protein expression is significantly reduced, such that the two serine and the L-lysine salt can effectively inhibit the abnormal activation of the Notch signal channel;

Disclosed are a compound and use for and a method for treating aberrant Notch signaling diseases and as checkpoint kinase 1 inhibitors, or as double targeting inhibitors of both NOTCH1 and CHK1, and especially for cancer, using a heteroaromatic compound of general formulae (I), (II), (III), and (IV), or their pharmaceutically acceptable salt, a stereoisomeric, isotopic, tautomeric or polymorphic form, or prodrug thereof.